Benlysta, a drug to treat lupus, has received approval from European regulators to be marketed in Europe, the drug’s co-makers, Human Genome Sciences Inc. of Rockville, and GlaxoSmithKline, its London-based parent, announced. The European approval came two days after Benlysta, ...
Tagged with: approval drug europe FDA glaxosmithkline lupus maryland rockville treatment u.s. food and drug administration
Read More »